

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Liora CAHALON et al

Serial No.: 10/002,145

Filed: December 5, 2001

For: NOVEL ANTI-CANCER THERAPEUTIC COMPOUNDS

Examiner: HUI, SAN MING R

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

10/20/2005 HALI11 00000081 501407 10002145
01 FC:1806 180.00 DA


Respectfully submitted,

Respectfully submitted,
Martri O. Moynihan

Martin Moynihan
Registration No. 40,338

Dated: October 3, 2005

~~1614~~ ~~1FW~~ ~~9~~



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/002,145
				Filing Date	December 5, 2001
				First Named Inventor	Liora CAHALON et al
				Art Unit	1614
				Examiner Name	HUI, SAN MING R
Sheet		of		Attorney Docket Number	24214

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-4,882,318	11-21-1989	Vlodavsky et al.	
	2	US-6,750,207	06-15-2004	Cohen et al.	
	3	US-4,401,662	08-30-1983	Lormeau et al.	
	4	US-4,446,314	01-1-1984	Jordan	
	5	US-4,539,398	03-3-1985	Rosenberg	
	6	US-4,607,025	08-19-1986	Petitou et al.	
	7	US-4,727,063	02-23-1988	Naggi et al.	
	8	US-4,774,231	09-27-1988	Petitou et al.	
	9	US-4,801,583	01-31-1989	Petitou et al.	
	10	US-4,818,816	04-4-1989	Petitou et al.	
	11	US-4,889,808	12-26-1989	Rappaport	
	12	US-4,933,326	06-12-1990	Bianchini et al.	
	13	US-4,943,630	07-24-1990	Jacquinet et al.	
	14	US-4,973,580	11-27-1990	Mascellani et al.	
	15	US-4,981,955	01-1-1991	Lopez	
	16	US-4,987,223	01-22-1991	Choay et al.	
	17	US-4,990,502	05-5-1991	Lormeau et al.	
	18	US-5,010,063	04-23-1991	Piani et al.	
	19	US-5,034,520	07-23-1991	Lormeau et al.	
	20	US-6,020,323	01-1-2000	Cohen et al.	
	21	US-5,861,382	01-19-1999	Cohen et al.	
	22	US-2004/0198697	07-7-2004	Cohen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	23	PCT WO 03/047501	06-12-2003	Cahalon et al.		
	24	EP 0669827	05-23-2001	Cohen et al.		
	25	EP 0114589	01-1-1984	Folkman et al.		
	26	EP 0375976	04-4-1990	Cohen et al.		
	27	EP 0394971	10-31-1990	Bergendahl et al.		
	28	PCT WO 88/05301	07-28-1988	Parish et al.		
	29	PCT WO 90/03791	04-19-1990	Diferrante		
	30	PCT WO 94/11006	05-26-1994	Cohen et al.		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known


Application Number	10/002,145
Filing Date	December 5, 2001
First Named Inventor	Liora CAHALON et al
Group Art Unit	1614
Examiner Name	HUI, SAN MING R
Attorney Docket Number	24214


Sheet

Of

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	31	Timar et al. "Interactions of Exogenous Heparan Sulfate with Tumor Cells of Different Metastatic Phenotype", Invasion Metastasis, 10: 301-315, 1990.	
	32	Murdoch et al. "Chemokine Receptors and Their Role in Inflammation and Infectious Diseases", Blood, 95(10): 3032-3043, 2000.	
	33	Oberlin et al. "The CXC Chemokine SDF-1 Is the Ligand for LESTR/Fusin and Prevents Infection by T-Cell-Line-Adapted HIV-1", Nature, 382: 833-835, 1996.	
	34	Nagasawa et al. "Defects of B-Cell Lymphopoiesis and Bone-Marrow Myelopoiesis in Mice Lacking the CXC Chemokine PBSF/SDF-1", Nature, 382: 635-638, 1996.	
	35	McGrath et al. "Embryonic Expression and Function of the Chemokine SDF-1 and Its Receptor, CXCR4", Developmental Biology, 213: 442-456, 1999.	
	36	Ponomaryov et al. "Induction of the Chemokine Stromal-Derived Factor-1 Following DNA Damage Improves Human Stem Cell Function", The Journal of Clinical Investigation, 106(11): 1331-1339, 2000.	
	37	Gonzalo et al. "Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1 α in the Inflammatory Component of Allergic Airway Disease", The Journal of Immunology, 165: 499-508, 2000.	
	38	Peled et al. "The Chemokine SDF-1 Stimulates Integrin-Mediated Arrest of CD34+ Cells on Vascular Endothelium Under Shear Flow", The Journal of Clinical Investigation, 104(9): 1199-1211, 1999.	
	39	Peled et al. "Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4", Science, 283: 845-848, 1999.	
	40	Sawada et al. "Disturbed CD4+ T Cell Homeostasis and In Vitro HIV-1 Susceptibility in Transgenic Mice Expressing T Cell Line-Tropic HIV-1 Receptors", Journal of Experimental Medicine, 187(9): 1439-1449, 1998.	
	41	Aiuti et al. "The Chemokine SDF-1 Is A Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides A New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood", Journal of Experimental Medicine, 185(1): 111-120, 1997.	
	42	Peled et al. "The Chemokine SDF-1 Activates the Integrins LFA-1, VLA-4, and VLA-5 on Immature Human CD34+ Cells: Role in Transendothelial/Stromal Migration and Engraftment of NOD/SCID Mice", Blood, 95(11): 3289-3296, 2000.	
	43	Edinger et al. "Noninvasive Assessment of Tumor Cell Proliferation in Animal Models", Neoplasia, 1(4): 303-310, 1999.	
	44	Contag et al. "Bioluminescent Indicators in Living Mammals", Nature Medicine, 4(2): 245-247, 1998.	
	45	Condiotti et al. "Effect of Interleukin-12 on Antitumor Activity of Human Umbilical Cord Blood and Bone Marrow Cytotoxic Cells", Experimental Hematology, 26: 571-579, 1998.	
	46	Chowers et al. "Disaccharides Derived From Heparin or Heparan Sulfate Regulate IL-8 and IL-1 β Secretion by Intestinal Epithelial Cells", Gastroenterology, 120: 449-459, 2001.	
	47	Goodman et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs", The Pharmacological Basis of Therapeutics, II(Chap.55): 1312-1315, 1992.	
	48	Vlodavsky et al. "Modulation of Neovascularization and Metastasis by Species of Heparin", Adv. Exp. Med. Biol., 13: 317-327, 1992.	
	49	Hershkoviz et al. "Disaccharides Generated From Heparan Sulphate or Heparin Modulate Chemokine-Induced T-Cell Adhesion to Extracellular Matrix", Immunology, 99: 87-93, 2000.	





50	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed From the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA, 92: 5037-5041, 1995.	
51	Cahalon et al. "Heparin Disaccharides Inhibit Tumor Necrosis Factor- α Production by Macrophages and Arrest Immune Inflammation in Rodents", International Immunology, 9(10): 1517-1522, 1997.	
52	Horvath et al. "Low Dose Heparin and Early Kidney Transplant Function", Australian and New Zealand Journal of Medicine, 5: 537-539, 1975.	
53	Kariya et al. "Preparation of Unsaturated Disaccharides by Eliminative Cleavage of Heparin and Heparan Sulfate With Heparitinases", Comp. Biochem. Physiol., 103B: 473-479, 1992.	
54	Lider et al. "Inhibition of T Lymphocyte Heparanase by Heparin Prevents T Cell Migration and T Cell-Mediated Immunity", European Journal of Immunology, 20: 493-499, 1990.	
55	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparins", The Journal of Clinical Investigation, 83: 752-756, 1989.	
56	Neparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase", Nature, 310: 241-244, 1984.	
57	Psuja "Affinity of Binding of Radiolabeled (125 I) Heparin and Low Molecular Weight Heparin Fraction CY 222 to Endothelium in Culture", Folia Haematol., 114(3): 429-436, 1987.	
58	Toivonen et al. "Rat Adjuvant Arthritis as A Model to Test Potential Antirheumatic Agents", Meth. and Find. Exptl. Clin. Pharmacol., 4(6): 359-363, 1982.	
59	Asselot et al. "Heparin Fragments Regulate Collagen Phenotype and Fibronectin Synthesis in the Skin of Genetically Diabetic Mice", Biochemical Pharmacology, 38(6): 895-899, 1989.	
60	Asselot-Chapel et al. "Biosyntheses of Interstitial Collagens and Fibronectin by Porcine Aorta Smooth Muscle Cells. Modulation by Low-Molecular-Weight Heparin Fragments", Biochimica et Biophysica Acta, 993: 240-244, 1989.	
61	Rodén et al. "Heparin - An Introduction", Heparin and Related Polysaccharides, Plenum Press, P.1-20, 1992.	
62	Bezouška et al. "Oligosaccharide Ligands for NKR-P1 Protein Activate NK Cells and Cytotoxicity", Nature, 372: 150-157, 1994.	
63	Müller et al. "Involvement of Chemokine Receptors in Breast Cancer Metastasis", Nature, 410: 50-56, 2001.	
64	Sehgal et al. "Molecular Characterization of CXCR-4: A Potential Brain Tumor-Associated Gene", Journal of Surgical Oncology, 69: 239-248, 1998.	
65	Sehgal et al. "CXCR-4, A Chemokine Receptor, Is Overexpressed in and Required for Proliferation of Glioblastoma Tumor Cells", Journal of Surgical Oncology, 69: 99-104, 1998.	
66	Rossi et al. "The Biology of Chemokines and Receptors", Annu. Rev. Immunol., 18: 217-242, 2000.	
67	Braun et al. "The CC Chemokine CK β -11/MIP-3 β /ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells", The Journal of Immunology, 164: 4025-4031, 2000.	
68	Bleul et al. "The Lymphocyte Chemoattractant SDF-1 Is A Ligand for LESTR/Fusin and Blocks HIV-1 Entry", Nature, 382: 829-833, 1996.	

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.